Who Supplies Ezetimibe to India from SOUTH AFRICA

To import finished pharmaceutical formulations containing Ezetimibe (HS Code 30049099) into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the importer and the product be registered. The importer must obtain an Import License from the Directorate General of Foreign Trade (DGFT), which requires a valid Importer Exporter Code (IEC). The product must be registered with CDSCO, necessitating submission of Form 40/41, along with a No Objection Certificate (NOC) from the manufacturer. The registration process includes providing a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data compliant with ICH Zone IV guidelines. The timeline for import drug registration varies but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory workload. For Ezetimibe formulations, specific requirements include detailed product dossiers, evidence of bioequivalence, and compliance with Indian Pharmacopoeia standards.

Imported finished pharmaceutical formulations containing Ezetimibe are subject to quality testing by CDSCO-approved laboratories. Each batch must be accompanied by a Certificate of Analysis (CoA) issued by the manufacturer and a batch-wise certificate from the testing laboratory. Stability data demonstrating compliance with ICH Zone IV conditions is required. Upon arrival at Indian ports, customs drug inspectors conduct inspections to verify the authenticity of documents and samples. If a batch fails quality testing, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance. Common quality issues identified in imports include deviations in dissolution profiles and impurity levels exceeding permissible limits.

Between 2024 and 2026, CDSCO has implemented stricter regulations for the import of pharmaceutical products, including mandatory import registration and licensing. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of finished formulation imports. Bilateral agreements between India and South Africa have focused on mutual recognition of GMP standards, facilitating smoother trade in pharmaceutical products.

India imports finished Ezetimibe formulations due to the demand for branded products, specific dosage forms not produced domestically, and the need to meet therapeutic requirements. The market size for Ezetimibe formulations in India is substantial, with a growing patient population requiring cholesterol-lowering medications. Domestic manufacturers may not fully meet the demand, leading to reliance on imports to bridge the gap.

The Basic Customs Duty (BCD) for HS Code 30049099 is 10%. An Integrated Goods and Services Tax (IGST) of 12% is applicable on imported goods. A Social Welfare Surcharge (SWS) of 10% is levied on the BCD. There are no exemptions or preferential rates for imports from South Africa. The total landed duty percentage is calculated by summing the BCD, SWS, and IGST, resulting in a cumulative duty burden on imported goods.

India sources finished Ezetimibe formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. South African suppliers offer formulations that may not be produced domestically, providing a competitive advantage in terms of product diversity and quality. Other suppliers include China, Germany, and the United States; however, South Africa's share in the Indian market is notable due to these factors.

India imports finished Ezetimibe formulations from South Africa due to the availability of patented formulations, specialized dosage forms, and high-quality manufacturing standards. South African suppliers offer formulations that may not be produced domestically, providing a competitive advantage in terms of product diversity and quality.

Compared to other origins such as China, the European Union, and the United States, South Africa offers competitive pricing, adherence to international quality standards, and compliance with regulatory requirements. South African manufacturers are known for their reliability and consistency in product quality, making them a preferred choice for Indian importers.

Potential risks for Indian importers include reliance on a single source, currency fluctuations, regulatory changes, quality control issues, and shipping disruptions. To mitigate these risks, importers should diversify their supplier base, monitor currency exchange rates, stay updated on regulatory changes, conduct regular quality audits, and establish contingency plans for shipping disruptions.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory costs.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers, including audits of manufacturing facilities and review of quality certifications.

1. 1DGFT Importer Exporter Code (IEC): Obtain a valid IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO by submitting Form 40/41.
3. 3Drug Import License: Apply for and obtain a Drug Import License from CDSCO.
4. 4No Objection Certificate (NOC): Secure an NOC from the manufacturer.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

1. 1DGFT Importer Exporter Code (IEC): Obtain a valid IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with CDSCO by submitting Form 40/41.
3. 3Drug Import License: Apply for and obtain a Drug Import License from CDSCO.
4. 4No Objection Certificate (NOC): Secure an NOC from the manufacturer.
5. 5Customs Broker: Engage a licensed customs broker for clearance procedures.
6. 6Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

SECTION: